Future LRMN Events


LRMN & Miltenyi

The May 2014 meeting of the LRMN will be featuring three cell therapy visionaries – individuals who have been championing the stem cell field and providing sector leadership for over a decade. This meeting is kindly supported by Miltenyi Biotec and is free of charge to attend.

Miltenyi Biotec provides cutting-edge products and services that advance biomedical research and cellular therapy, with innovative tools that support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, their integrated technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The CliniMACS® System and MACS® GMP Products enable GMP-compliant cellular product manufacturing and the next generation of automated, closed-system cell processing, the CliniMACS Prodigy®, is now here. Miltenyi Biotec has more than 1,300 employees in 22 countries and is 25 years old this year!

The meeting will take place on Monday 19th May 2014 at 6.00 pm in the Haldane Room, Wilkins Building, University College London – A short walk from Euston Square, Goodge Street and Warren Street Tube Stations and Euston Station.

Registration: 6.00 - 6.30 pm
Presentations: 6.30 - 8.25 pm
Networking Reception 8.25 - 10.00 pm

********

AGENDA:

18.00 - Registration over tea and coffee in the Haldane Room (Wilkins Building, UCL)

18.25 - Walk up to the Gustave Tuck Lecture Theatre (Wilkins Building, UCL)

18.30 - Welcome - Dr. Emily Culme-Seymour, LRMN (London, UK) and Dr. Oliver Bartelsen, Miltenyi Biotec (nr Cologne, Germany)

18.35 - "Cell therapy commercialisation - a multinational opportunity" - Dr. Silviu Itescu, Mesoblast (Melbourne, Australia)

19.05 - Q & A

19.10 - "Pushing the limits: How The New York Stem Cell Foundation and a new model of research are leading the path to cures" - Susan Solomon, The New York Stem Cell Foundation (New York, NY, US)

19.40 - Q & A

19.45 - "Emerging Opportunities in Regenerative Medicine" - Dr. Gil Van Bokkelen, Athersys (Cleveland, OH, US)

20.15 - Q & A

20.20 - Closing remarks - Prof. Chris Mason, Advanced Centre for Biochemical Engineering, UCL (London, UK) and Dr. Oliver Bartelsen, Miltenyi Biotec (nr Cologne, Germany)

20.25 - 22.00 - LRMN Reception - Network whilst enjoying a glass of wine or two in the Haldane Room (Wilkins Building, UCL)

********

SPONSORS + PARTNERS:

CORPORATE SPONSOR:
Miltenyi Biotec
PROMOTIONAL SUPPORT: '
Regenerative Medicine'

*******

PLEASE NOTE THAT DUE TO LECTURE THEATRE SEATING CAPACITY, IF YOU WISH TO ATTEND THIS EVENT YOU MUST REGISTER, OTHERWISE UNFORTUNATELY YOU WILL NOT BE ABLE TO GAIN ADMISSION. Seat allocation is on a first come, first served basis. If you wish to attend, all that is required is to email office@lrmn.com and type 'I will attend' in the subject box. Please only register if you can definitely make the meeting. If you have to cancel later do please let us know.

The LRMN Team very much look forward to welcoming you at 6.00 pm on Monday 19th May 2014 for an event that will focus on the very latest in the global cell therapy sector.

---------------

LRMN & Cell Therapy Catapult

The LRMN is working together again with the Cell Therapy Catapult to hold a second event in Summer 2014.

The Catapult is a centre of excellence in the translation of cell therapies from "bench to bedside". Its vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy, making it a location for business start-up and growth. Based in London at Guy's Hospital, the centre plans to work in collaboration with others to take products through early clinical trials, providing business, clinical, technical, manufacturing and regulatory expertise and to facilitate access to the NHS.

More information on
this event will be provided in due course, including the finalised date and the programme. Invitations will be sent out by email to the LRMN mailing list as usual.

---------------